Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To demonstrate the use of cost-effectiveness analysis to assess the economic impact of donepezil in the treatment of mild or moderate AD. BACKGROUND: Cost-effectiveness analyses show the relationship between resources used (costs) and health benefits achieved (effects) for an intervention compared with an alternative strategy. METHODS: We developed a model to estimate the incremental cost-effectiveness of donepezil compared with no treatment. We determined costs per quality-adjusted life-years gained, a measurement that enhances the comparability of diverse studies. The model projects the progression of AD patients into more severe disease stages and into nursing homes. Data from a randomized clinical trial of donepezil were used to assess the drug's impact on the 6-week probabilities of progression. Data on the costs and health-related quality of life associated with different disease stages and settings were taken from published estimates and our companion cross-sectional study, respectively. RESULTS: Donepezil costs are partially offset by a reduction in the costs of care due to enhancement in cognitive functioning and the delay to more costly disease stages and settings. The magnitude of this cost offset and of the effect of donepezil on health-related quality of life depends on the model's assumptions about the duration of the drug effect, where controlled data are lacking. If the drug effect exceeds 2 years, the model predicts that for mild AD the drug would pay for itself in terms of cost offsets. CONCLUSIONS: The results of the cost-effectiveness model presented here suggest that donepezil may be cost-effective but additional controlled data on long-term drug efficacy are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Self-citationThe Markov process in medical prognosis
Beck, J. R., & Pauker, S. G. (1983) · Medical Decision Making · doi:10.1177/0272989x8300300403 · Cited by 957
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626
Cited by
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Furlong, W. J., Feeny, D. H., Torrance, G. W., & Barr, R. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002092 · Cited by 751
A rational framework for decision making by the National Institute for Clinical Excellence (NICE)
Claxton, K., Sculpher, M., & Drummond, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09832-x · Cited by 456
Preference-Based Measures in Economic Evaluation in Health Care
Neumann, P. J., Goldie, S. J., & Weinstein, M. C. (2000) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.21.1.587 · Cited by 295
Self-citation
Metadata
- Authors
- Neumann, P. J., Hermann, R. C., Kuntz, K. M., Araki, S. S., Duff, S. B., Leon, J., Berenbaum, P. A., Goldman, P. A., Williams, L. W., & Weinstein, M. C.
- Venue
- Neurology
- Published
- 1999-04
- Volume
- 52
- Issue
- 6
- Pages
- 1138-1138
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2039585634
- Cited by
- 244
- References
- 6
- FWCI
- 57.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. https://app.cochat.ai/papers/10.1212/wnl.52.6.1138
- The paper
- Neumann, P. J., Hermann, R. C., Kuntz, K. M., Araki, S. S., Duff, S. B., Leon, J., Berenbaum, P. A., Goldman, P. A., Williams, L. W., & Weinstein, M. C. (1999). Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology. https://doi.org/10.1212/wnl.52.6.1138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.